Basis for dosing time-dependent change in the anti-tumor effect of imatinib in mice

Area of Science:

• Oncology
• Pharmacology
• Cancer Biology

Background:

• Receptor tyrosine kinases play a crucial role in tumor progression.
• Imatinib mesylate (Gleevec) is a tyrosine kinase inhibitor targeting Abl, KIT, and PDGF receptors.
• Developing effective therapeutic agents for malignant cancers is a priority.

Purpose of the Study:

• To investigate the influence of imatinib dosing time on tumor growth inhibition in mice.
• To determine the relationship between administration time and imatinib's anti-tumor and anti-angiogenic effects.
• To explore the impact of dosing schedule on imatinib's inhibitory activity against specific tyrosine kinases.

Main Methods:

• Tumor-bearing mice were housed under controlled light/dark cycles.
• Imatinib was administered intraperitoneally (50 mg/kg) during either the early light or early dark phase.
• Tyrosine kinase activity (PDGF receptors, KIT, Abl) and tumor growth were monitored.

Main Results:

• Imatinib administration in the early light phase resulted in more severe inhibition of tumor growth compared to the early dark phase.
• The observed dosing time-dependency in anti-tumor effects correlated with imatinib's anti-angiogenic effects.
• Imatinib's inhibitory effect on PDGF receptor activity, but not KIT or Abl, varied with administration time, closely mirroring anti-tumor effects.

Conclusions:

• The anti-tumor efficacy of imatinib is significantly influenced by its administration timing.
• Optimizing imatinib dosing schedules, especially during periods of increased PDGF receptor activity, can enhance therapeutic outcomes.
• Strategic administration timing holds potential for maximizing the clinical efficacy of imatinib in cancer treatment.